Search research articles
Contact Us
Filters
Showing results (141-150 of 144) with videos related to
Page
of 15
Sort By:
You have reached the last page of results.
This site can display upto 144 results.
The Korean Journal of Internal Medicine
|
May 22, 2015
Reference interval for thyrotropin in a ultrasonography screened Korean population
Mijin Kim, Tae Yong Kim, Soo Han Kim, et al.
Korean Circulation Journal
|
May 20, 2024
Efficacy and Safety of Sirolimus-Eluting Stent With Biodegradable Polymer Ultimaster™ in Unselected Korean Population: A Multicenter, Prospective, Observational Study From Korean Multicenter Ultimaster Registry
Soohyung Park, Seung-Woon Rha, Byoung Geol Choi, et al.
Anticancer Research
|
September 30, 2024
PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC
Insu Kim, Sun Ha Choi, Shin Yup Lee, et al.
Translational Lung Cancer Research
|
February 9, 2026
Clinical implications of plasma EGFR T790M and ctDNA shedding across metastatic sites in plasma- or tissue-confirmed EGFR-mutant non-small cell lung cancer treated with lazertinib: a prospective multicenter cohort study
Min Jee Kim, Junghee Jung, Wonjun Ji, et al.
Page
of 15
Search research articles
Search
Showing results (141-150 of 144) with videos related to
Sort By:
Page
of 15
You have reached the last page of results.
This site can display upto 144 results.
The Korean Journal of Internal Medicine
|
May 22, 2015
Reference interval for thyrotropin in a ultrasonography screened Korean population
Mijin Kim, Tae Yong Kim, Soo Han Kim, et al.
Korean Circulation Journal
|
May 20, 2024
Efficacy and Safety of Sirolimus-Eluting Stent With Biodegradable Polymer Ultimaster™ in Unselected Korean Population: A Multicenter, Prospective, Observational Study From Korean Multicenter Ultimaster Registry
Soohyung Park, Seung-Woon Rha, Byoung Geol Choi, et al.
Anticancer Research
|
September 30, 2024
PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC
Insu Kim, Sun Ha Choi, Shin Yup Lee, et al.
Translational Lung Cancer Research
|
February 9, 2026
Clinical implications of plasma EGFR T790M and ctDNA shedding across metastatic sites in plasma- or tissue-confirmed EGFR-mutant non-small cell lung cancer treated with lazertinib: a prospective multicenter cohort study
Min Jee Kim, Junghee Jung, Wonjun Ji, et al.
Page
of 15